Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pilar Lim

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 26, 2016
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depressionJustine M Kent, Ella Daly, Iva Kezic, et al.
The Journal of Clinical Psychiatry|July 7, 2017
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus MeetingPhillip B Chappell, Michelle Stewart, Larry Alphs, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
The International Journal of Neuropsychopharmacology|January 13, 2022
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant DepressionGuang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology|November 18, 2021
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With SchizophreniaDean Najarian, Panna Sanga, Steven Wang, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 9, 2021
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy StudyRachel Ochs-Ross, Ewa Wajs, Ella J Daly, et al.
CNS Drugs|July 8, 2021
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III StudiesRichard L Doty, Vanina Popova, Crystal Wylie, et al.
Marine Biotechnology (New York, N.Y.)|January 14, 2004
Platelet aggregation inhibitors from Philippine marine invertebrate samples screened in a new microplate assaySheila Marie V Pimentel, Zenaida P Bojo, Amy V D Roberto, et al.
JAMA|December 21, 2017
Guidelines for the Content of Statistical Analysis Plans in Clinical TrialsCarrol Gamble, Ashma Krishan, Deborah Stocken, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyVanina Popova, Ella J Daly, Madhukar Trivedi, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 26, 2016
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depressionJustine M Kent, Ella Daly, Iva Kezic, et al.
The Journal of Clinical Psychiatry|July 7, 2017
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus MeetingPhillip B Chappell, Michelle Stewart, Larry Alphs, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
The International Journal of Neuropsychopharmacology|January 13, 2022
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant DepressionGuang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology|November 18, 2021
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With SchizophreniaDean Najarian, Panna Sanga, Steven Wang, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 9, 2021
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy StudyRachel Ochs-Ross, Ewa Wajs, Ella J Daly, et al.
CNS Drugs|July 8, 2021
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III StudiesRichard L Doty, Vanina Popova, Crystal Wylie, et al.
Marine Biotechnology (New York, N.Y.)|January 14, 2004
Platelet aggregation inhibitors from Philippine marine invertebrate samples screened in a new microplate assaySheila Marie V Pimentel, Zenaida P Bojo, Amy V D Roberto, et al.
JAMA|December 21, 2017
Guidelines for the Content of Statistical Analysis Plans in Clinical TrialsCarrol Gamble, Ashma Krishan, Deborah Stocken, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyVanina Popova, Ella J Daly, Madhukar Trivedi, et al.
Pageof 5